PMID- 27858176
OWN - NLM
STAT- MEDLINE
DCOM- 20170412
LR  - 20181113
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
VI  - 36
IP  - 2
DP  - 2017 Feb
TI  - Serum level of reactive oxygen metabolites (ROM) at 12 weeks of treatment with 
      biologic agents for rheumatoid arthritis is a novel predictor for 52-week 
      remission.
PG  - 309-315
LID - 10.1007/s10067-016-3479-3 [doi]
AB  - We have shown that serum levels of reactive oxygen metabolites (ROM) were 
      associated with C-reactive protein (CRP) and disease activity score based on the 
      examination of 28 joints (DAS28) in patients with rheumatoid arthritis (RA); 
      however, their clinical significance as biomarkers has not been elucidated. 
      Forty-eight biologic agent (BA)-naive RA patients were included in this study. 
      Associations between serum levels of ROM, CRP, matrix metalloproteinase-3 
      (MMP-3), DAS28-erythrocyte sedimentation rate (ESR), and Health Assessment 
      Questionnaire (HAQ) at 12 weeks of treatment and DAS28 (ESR) remission at 
      52 weeks (52-week remission) were investigated. The ROM serum level at baseline 
      in the remission group (n = 34) was 527 +/- 132 Carratelli units (U.Carr) (normal 
      range <300), decreased to 335 +/- 79.1 at 4 weeks, and remained low thereafter. In 
      the non-remission group (n = 14), the ROM serum level at baseline was 
      592 +/- 113 U.Carr, decreased to 450 +/- 152 at 4 weeks, but gradually increased 
      thereafter. Among significantly different factors at 12 weeks between the 
      remission and non-remission groups, ROM and DAS28 (ESR) were identified as 
      predictors of 52-week remission (p = 0.045, odds ratio 0.985, 95% confidence 
      interval 0.97-1.000 for ROM). The cutoff value of ROM was determined to be 
      381.5 U.Carr (sensitivity 0.833, specificity 0.871). These results show that 
      serum ROM levels can predict remission with high accuracy and could be a useful 
      biomarker for achieving remission in the current treat-to-target strategy for RA.
FAU - Nakajima, Arata
AU  - Nakajima A
AD  - Department of Orthopaedics, Toho University Sakura Medical Center, 564-1 
      Shimoshizu, Sakura-shi, Chiba, 285-8741, Japan. a-nakaji@sf7.so-net.ne.jp.
AD  - Department of Rheumatology, Toho University Sakura Medical Center, 564-1 
      Shimoshizu, Sakura-shi, Chiba, 285-8741, Japan. a-nakaji@sf7.so-net.ne.jp.
FAU - Aoki, Yasuchika
AU  - Aoki Y
AD  - Department of General Medical Sciences, Graduate School of Medicine, Chiba 
      University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, 260-8677, Japan.
AD  - Department of Orthopaedic Surgery, Eastern Chiba Medical Center, 3-6-2 
      Okayamadai, Togane-shi, Chiba, 283-8686, Japan.
FAU - Sonobe, Masato
AU  - Sonobe M
AD  - Department of Orthopaedics, Toho University Sakura Medical Center, 564-1 
      Shimoshizu, Sakura-shi, Chiba, 285-8741, Japan.
FAU - Takahashi, Hiroshi
AU  - Takahashi H
AD  - Department of Orthopaedics, Toho University Sakura Medical Center, 564-1 
      Shimoshizu, Sakura-shi, Chiba, 285-8741, Japan.
FAU - Saito, Masahiko
AU  - Saito M
AD  - Department of Orthopaedics, Toho University Sakura Medical Center, 564-1 
      Shimoshizu, Sakura-shi, Chiba, 285-8741, Japan.
FAU - Nakagawa, Koichi
AU  - Nakagawa K
AD  - Department of Orthopaedics, Toho University Sakura Medical Center, 564-1 
      Shimoshizu, Sakura-shi, Chiba, 285-8741, Japan.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20161117
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biological Products)
RN  - 0 (Biomarkers)
RN  - 0 (Reactive Oxygen Species)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antirheumatic Agents/*therapeutic use
MH  - Area Under Curve
MH  - Arthritis, Rheumatoid/blood/*drug therapy
MH  - Biological Products/*therapeutic use
MH  - Biomarkers/metabolism
MH  - Blood Sedimentation
MH  - C-Reactive Protein/metabolism
MH  - Humans
MH  - Matrix Metalloproteinase 3/metabolism
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Odds Ratio
MH  - Reactive Oxygen Species/*blood
MH  - Remission Induction
MH  - Surveys and Questionnaires
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Biologic agents
OT  - Predictor
OT  - Reactive oxygen metabolites (ROM)
OT  - Remission
OT  - Rheumatoid arthritis
EDAT- 2016/11/20 06:00
MHDA- 2017/04/13 06:00
CRDT- 2016/11/19 06:00
PHST- 2016/10/01 00:00 [received]
PHST- 2016/11/07 00:00 [accepted]
PHST- 2016/10/28 00:00 [revised]
PHST- 2016/11/20 06:00 [pubmed]
PHST- 2017/04/13 06:00 [medline]
PHST- 2016/11/19 06:00 [entrez]
AID - 10.1007/s10067-016-3479-3 [pii]
AID - 10.1007/s10067-016-3479-3 [doi]
PST - ppublish
SO  - Clin Rheumatol. 2017 Feb;36(2):309-315. doi: 10.1007/s10067-016-3479-3. Epub 2016 
      Nov 17.